MF

Michael Finney

Board director for public and private companies

San Francisco, California

Invests in

Stages:

  • Min Investment:

    $250,000.00
  • Max Investment:

    $750,000.00
  • Target Investment:

    $500,000.00

Work Experience

  • Board Chair

    2023

  • Member Board of Directors

    2007

  • Interim Chief Executive Officer

    2024 - 2024

    I've served on the Board of Directors since 2007, became Chair in 2023, and Interim CEO in January 2024. Previously, I served as CEO for over two years, July 2009 to October 2011. Vaxart is a game-changing company with its technology for oral vaccination, and has an excellent team.

  • CEO

    2009 - 2011

    Having served on the board since 2007, in 2009 I came in as acting CEO and ended up staying over 2 years. In this time, we closed a $12 million Series B, completed preclinical work, ran a Phase I clinical trial, and hired a permanent CEO.

  • Board Chair

    2014

  • Director

    2019

    Enabling single-cell genomics for solid tissues

  • Board Chair

    2019

    Commercializing technology from the Collins lab at UC Berkeley

  • Managing Director

    2004

  • Director

    2016

    Reagent systems for DNA sequencing

  • Director

    1998

  • Board Chair

    2005

    Board Chair, December 2015-present

  • Director and Permanent Member

    1999

    Formerly named G Corp, TGP is a non-profit corporation that is responsible for, among other things, the AGBT Genomics meeting. The meeting has been held every February since 2000. It provides an opportunity for academics and commercial companies in the field of genomics to exchange the latest advances.

  • Member

    2006